- Home
- IMCR vs JANX Comparison
IMCR vs JANX Comparison
Compare IMCR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- JANX
- Stock Information
- Founded
- IMCR 2008
- JANX 2017
- Country
- IMCR United Kingdom
- JANX United States
- Employees
- IMCR N/A
- JANX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- JANX Health Care
- Exchange
- IMCR Nasdaq
- JANX Nasdaq
- Market Cap
- IMCR 1.8B
- JANX 1.4B
- IPO Year
- IMCR 2021
- JANX 2021
- Fundamental
- Price
- IMCR $33.38
- JANX $24.87
- Analyst Decision
- IMCR Buy
- JANX Strong Buy
- Analyst Count
- IMCR 10
- JANX 8
- Target Price
- IMCR $58.13
- JANX $90.63
- AVG Volume (30 Days)
- IMCR 315.0K
- JANX 892.8K
- Earning Date
- IMCR 08-07-2025
- JANX 08-07-2025
- Dividend Yield
- IMCR N/A
- JANX N/A
- EPS Growth
- IMCR N/A
- JANX N/A
- EPS
- IMCR N/A
- JANX N/A
- Revenue
- IMCR $356,145,000.00
- JANX $439,000.00
- Revenue This Year
- IMCR $27.43
- JANX N/A
- Revenue Next Year
- IMCR $8.64
- JANX $1,470.83
- P/E Ratio
- IMCR N/A
- JANX N/A
- Revenue Growth
- IMCR 26.78
- JANX N/A
- 52 Week Low
- IMCR $23.15
- JANX $21.97
- 52 Week High
- IMCR $39.33
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- IMCR 49.64
- JANX 51.13
- Support Level
- IMCR $31.02
- JANX $23.96
- Resistance Level
- IMCR $33.73
- JANX $25.93
- Average True Range (ATR)
- IMCR 1.49
- JANX 1.55
- MACD
- IMCR -0.03
- JANX 0.06
- Stochastic Oscillator
- IMCR 44.61
- JANX 61.91
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.